A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.

Multiple myeloma (MM) is characterized by complex genetic abnormalities whose complexity signifies varying degree of chromosomal instability (CIN). In this study, we introduced a novel CIN measure, chromosome instability genome event count (CINGEC), which considered both copy number aberrations and...

Full description

Bibliographic Details
Main Authors: Tae-Hoon Chung, George Mulligan, Rafael Fonseca, Wee Joo Chng
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23840451/pdf/?tool=EBI
id doaj-f85a0564af5e41f999abd3cb5d8d4469
record_format Article
spelling doaj-f85a0564af5e41f999abd3cb5d8d44692021-03-04T12:09:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6636110.1371/journal.pone.0066361A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.Tae-Hoon ChungGeorge MulliganRafael FonsecaWee Joo ChngMultiple myeloma (MM) is characterized by complex genetic abnormalities whose complexity signifies varying degree of chromosomal instability (CIN). In this study, we introduced a novel CIN measure, chromosome instability genome event count (CINGEC), which considered both copy number aberrations and interstitial breakpoints from high-resolution genome-wide assays. When assessed in two aCGH MM datasets, higher CINGEC was associated with poor survival. We then derived a CINGEC-associated gene expression profile (GEP) signature, CINGECS, using a dataset that has both aCGH and GEP. Genes in CINGECS were mainly involved in DNA damage responses besides in aneuploidy and other generic oncogenic processes contrary to other CIN associated GEP signatures. Finally, we confirmed its survival association in three GEP datasets that encompassed newly diagnosed patients treated with transplant-based protocol with or without novel agents for induction as well as relapsed patients treated with bortezomib. Furthermore, CINGECS was independent of many GEP-based prognostic signatures. In conclusion, our novel CIN measure has definite biological and clinical significance in myeloma.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23840451/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Tae-Hoon Chung
George Mulligan
Rafael Fonseca
Wee Joo Chng
spellingShingle Tae-Hoon Chung
George Mulligan
Rafael Fonseca
Wee Joo Chng
A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
PLoS ONE
author_facet Tae-Hoon Chung
George Mulligan
Rafael Fonseca
Wee Joo Chng
author_sort Tae-Hoon Chung
title A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
title_short A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
title_full A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
title_fullStr A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
title_full_unstemmed A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
title_sort novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Multiple myeloma (MM) is characterized by complex genetic abnormalities whose complexity signifies varying degree of chromosomal instability (CIN). In this study, we introduced a novel CIN measure, chromosome instability genome event count (CINGEC), which considered both copy number aberrations and interstitial breakpoints from high-resolution genome-wide assays. When assessed in two aCGH MM datasets, higher CINGEC was associated with poor survival. We then derived a CINGEC-associated gene expression profile (GEP) signature, CINGECS, using a dataset that has both aCGH and GEP. Genes in CINGECS were mainly involved in DNA damage responses besides in aneuploidy and other generic oncogenic processes contrary to other CIN associated GEP signatures. Finally, we confirmed its survival association in three GEP datasets that encompassed newly diagnosed patients treated with transplant-based protocol with or without novel agents for induction as well as relapsed patients treated with bortezomib. Furthermore, CINGECS was independent of many GEP-based prognostic signatures. In conclusion, our novel CIN measure has definite biological and clinical significance in myeloma.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23840451/pdf/?tool=EBI
work_keys_str_mv AT taehoonchung anovelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT georgemulligan anovelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT rafaelfonseca anovelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT weejoochng anovelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT taehoonchung novelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT georgemulligan novelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT rafaelfonseca novelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
AT weejoochng novelmeasureofchromosomeinstabilitycanaccountforprognosticdifferenceinmultiplemyeloma
_version_ 1714803159426138112